MarketGrader Indexes – 2023 Performance Review
MarketGrader’s stock selection methodology shone in 2023, as 75% of our indexes outperformed their benchmarks in what turned out to be a strong year for most equity markets around the world.
MarketGrader’s stock selection methodology shone in 2023, as 75% of our indexes outperformed their benchmarks in what turned out to be a strong year for most equity markets around the world.
MarketGrader’s stock selection methodology shone in 2023, as 75% of our indexes outperformed their benchmarks in what turned out to be a strong year for most equity markets around the world.
Using the Barron’s 400 Index as a proxy for a portfolio holding GARP companies, the GARP vs. Size blog is a weekly summary of the
Using the Barron’s 400 Index as a proxy for a portfolio holding GARP companies, the GARP vs. Size blog is a weekly summary of the
Using the Barron’s 400 Index as a proxy for a portfolio holding GARP companies, the GARP vs. Size blog is a weekly summary of the
The best outcome of the recent U.S. election that health care investors could have hoped for was a divided government, and they got it (or
Using the Barron’s 400 Index as a proxy for a portfolio holding GARP companies, the GARP vs. Size blog is a weekly summary of the
Using the Barron’s 400 Index as a proxy for a portfolio holding GARP companies, the GARP vs. Size blog is a weekly summary of the performance of US equity markets aimed at informing readers the alpha that is attainable using a GARP focused stock picking strategy
Using the Barron’s 400 Index as a proxy for a portfolio holding GARP companies, the GARP vs. Size blog is a weekly summary of the
Using the Barron’s 400 Index as a proxy for a portfolio holding GARP companies, the GARP vs Size blog is a weekly summary of the
Using the Barron’s 400 Index as a proxy for a portfolio holding GARP companies, the GARP vs. Size blog is a weekly summary of the
MarketGrader’s stock selection methodology shone in 2023, as 75% of our indexes outperformed their benchmarks in what turned out to be a strong year for most equity markets around the world.
Investors in Chinese equities should move past macroeconomic concerns and focus instead on the country’s technological transformation.
Market Imbalance Sets Up Fundamental Investing for Big Comeback Here’s our list of some
In 2022 investors rediscovered the importance of capital allocation when money is no longer
Investors Continue to Underestimate the Impact Higher Interest Rates Are Having Across the Economy. Beware Expensive Large Cap Stocks.
Part 1 of 3. The Tactical Case for China With 2022 coming to an
The Barron’s 400 index approach is focused on consistency rather than market timing. To
MarketGrader’s ratings, which are designed to help investors identify the world’s best compounders of
Our Take on the 20th Party Congress of the Chinese Communist Party Clarity is
The Barron’s 400 Index (B400) started the week with a newly reconstituted roster of